Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Rule Reduces Plan Reassignments For Low-Income Enrollees

Executive Summary

CMS' new approach to setting the premium "benchmark" for low-income enrollees in Medicare drug plans will trim the number of enrollees who are reassigned each year - but not eliminate the issue

You may also be interested in...



Part D growth through MA plans

Membership in Medicare Advantage drug plans increased approximately 6 percent to 8 million following the 2008 open enrollment period, according to CMS enrollment data. Enrollment in stand-alone Medicare prescription drug plans rose by about 1.2 percent to 17.4 million. The largest gain in the MA-PD market was recorded by Humana, adding 92,000 to a total of 1.2 million, based on an analysis of enrollment numbers by Avalere Health. Market leader UnitedHealth added 21,600 MA-PD members for a total of approximately 1.3 million. However, UnitedHealth lost nearly 600,000 stand-alone PDP members in 2008 (to 4.1 million) and Humana lost about 290,000, to 3.2 million. Due to premium increases, United predicted it would lose up to 650,000 low-income PDP members in 2008 (1"The Pink Sheet," Oct. 1, 2007, p. 12). Humana also had forecast losses based on higher premiums (2"The Pink Sheet," Oct. 8, 2007, p. 18)...

Part D Enrollment, Formularies And Other Medicare Drug Coverage In Brief

Part D Membership Stability

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel